Abstract: Pain involves responses in which both peripheral and central mechanisms contribute to the generation of pain. Preclinical laboratory data have supported that a topical formulation of combined diclofenac and methadone (Diclometh) may alleviate local pain, and potentially, the side effect profile should be low. We hypothesized that antiallodynic and antihyperalgesic effects of Diclometh could be demonstrated in a human experimental pain model and that Diclometh would be safe to administer. Thus, the aims were as follows: (i) to compare two doses of Diclometh versus placebo; and (ii) to assess the safety profile of Diclometh. The study was a crossover, randomized, double-blind, placebo-controlled comparison of two doses of Diclometh gel (0.1% and 0.2%) administered topically in healthy participants. Nerve growth factor (NGF) and capsaicin intradermal injections were used as human pain models. Pressure stimulation, contact heat stimulation, hyperalgesia (pinprick stimulation) and allodynia (brush stimulation) to mechanical stimulation were performed in the area where capsaicin and NGF were injected. Side effects were recorded on a four-point Likert scale. Twenty-one men completed the study (mean age 26.14 AE 5.3). Diclometh 0.2% reduced the capsaicin-induced dynamic mechanical allodynia compared to placebo (primary end-point, p = 0.03). No other primary or secondary end-points were found significantly different (all p > 0.05). All side effects were reported as mild with no differences between treatments (p = 0.15). Indication of antiallodynic effect of Diclometh 0.2% was found. Additionally, it was demonstrated that Diclometh was safe to use.
The incidence of chronic pain is estimated to be 20% worldwide. Chronic pain, including neuropathic pain, involves neuronal responses in which both peripheral and central mechanisms contribute to the generation of spontaneous and stimulus-evoked pain. Although central mechanisms are important in the generation of pain, recently, peripheral processes have gained more attention as mechanisms of the hypersensitivity [1] .
Few patients with chronic pain obtain complete relief from the central drugs that are currently available, and more than half report inadequate relief [2] . Local analgesics are another option for pain management that may avoid many side effects associated with currently used central active drugs [3, 4] . These peripherally acting drugs can lead to a reduction in nociceptor activity and even stop pain before it is encoded, leading to some of the central consequences in neuropathic pain [5] . Topical agents such as lidocaine or capsaicin are widely used for peripheral neuropathic pain [4] .
Several mechanisms are involved in peripheral hypersensitivity such as involvement of TRPV1-immunoreactive nerves in painful skin [6] . Additionally, human and animal studies support the role of NMDA-nitric oxide systems in peripheral nociceptive transmission [7, 8] . Therefore, the use of combination therapy in topical agents has been suggested [9] . For example, in pre-clinical studies, topical opioid and nonsteroidal anti-inflammatory drugs demonstrated a synergistic interaction in a contact heat pain model [10] . Although a number of combinations of these drugs have been used for treatment of chronic neuropathic pain in clinical settings, only few have been systematically investigated and most have not been subjected to randomized, placebo-controlled trials [11, 12] .
The results of pre-clinical laboratory data have supported the initiation of a translationally controlled randomized study to evaluate the effects of the topical formulation of the combination diclofenac/methadone (Diclometh) in a human experimental pain study [10] . The hypothesis was that antiallodynic and antihyperalgesic effects of Diclometh could be demonstrated in models for pain and that Diclometh was safe to administer.
Thus, the aims were as follows: (i) to compare two doses of Diclometh versus placebo gel in human beings, where capsaicin and nerve growth factor (NGF) were used to mimic pain and (ii) to assess the safety profile of Diclometh. Study protocol. The study was conducted as a crossover, randomized, double-blind, placebo-controlled comparison of two doses of Diclometh gel (diclofenac plus methadone, 1:1) administered topically in 21 human healthy male participants. NGF and capsaicin intradermal injections were used as a human model of pain. The thigh was used for the NGF model, and in parallel, the forearm was used for the capsaicin model.
Methods
To avoid carry-over effects, either right or left sites were used for capsaicin and NGF injection, respectively, at each treatment period. Thus, right thigh and right arm were used at period 1 and 3, and left thigh and arm were used at period 2.
Each treatment period included two visits and was separated by a washout period of minimum 10 days. Each participant was contacted by telephone 30 days after the last dose for safety evaluation ( fig. 1 ). After obtaining demographic data and a general physical examination, eligible participants were enrolled into the study. During the first visit, participants were familiarized with different types of experimental pain testing. All testings were performed by well-trained researchers. Each participant was tested by the same researcher at the same time of the day on all study days.
Participants. Twenty-one healthy male volunteers participated in the study. Prior to inclusion, informed consent was obtained.
Inclusion criteria were as follows: males from the ages of 18 years to 65; intact skin in the area of drug application; able to read and understand Danish; willing and able to comply with the scheduled visits and trial procedures; northern European descent.
Exclusion criteria were as follows: known hypersensitivity to methadone and/or diclofenac; any diagnosed disease, which investigator concluded would affect the trial (including neurological and psychiatric disease); past or present history of substance abuse and/or patients using any illegal substances; use of prescription medicine and/or herbal medicine; use of over-the-counter medication 24 hr before and in each study period. Before inclusion, a physician conducted a routine health screening for each participant, ruling out any pain-related conditions.
Medication. Eligible participants were enrolled in the study and, after randomization, assigned to receive two different concentrations of Diclometh: [1] a combination of 0.1% diclofenac and 0.1% of methadone gel, [2] a gel with 0.2% diclofenac and 0.2% methadone or [3] placebo gel (vehicle only; Hospital Pharmacy Skanderborg, Denmark). At visit one in each period, 5 ml of the gel (Diclometh or placebo) was applied topically on the forearm. Thus, the total dose per visit was [1] 5 mg diclofenac combined with 5 mg methadone for the 0.1% gel and [2] 10 mg diclofenac combined with 10 mg methadone for the 0.2% gel. The gel was gently spread out in the area of approximately 4 cm in diameter and covered by Tegaderm dressing (3M Health Care, St. Paul, MN, USA) for 45 min. After 45 min., Tegaderm and gel rests were removed, and experimental tests as described below were performed (except pressure stimulation). On the next day (visit 2), only NGF effect was investigated. Thus, 22-26 hr after NGF injection, 5 ml Diclometh (0.1% or 0.2%)/placebo gel was applied topically into the area of NGF injection in the thigh, and this area was covered by Tegaderm dressing for 45 min. Thereafter, experimental tests as described below were performed. The Hospital Pharmacy Skanderborg, Denmark, was responsible for formulation, production and labelling of Diclometh gel (diclofenac and methadone) and placebo matching.
A computer-generated pseudo-random code was used to assign participants to one of three treatment groups. The code was generated by a competent person at the Hospital Pharmacy, Skanderborg, Denmark, not involved in other aspects of the study. Thus, participants and all study personnel were blinded to randomization.
Pain models and assessments. Following experimental baseline tests were performed on the forearm and thigh, to determine contact heat pain detection threshold (HPDT), hyperalgesia and allodynia to mechanical stimulation in the area where capsaicin and NGF were injected (capsaicin in forearm and NGF in the thigh). Furthermore, pressure pain detection threshold (PPDT) was determined at baseline and 25 hr after NGF injection, only on the thigh in the area where NGF was injected. The sensory abnormalities were identified with validated methods. All assessments (described below) were measured at baseline before NGF and capsaicin injection and at 30, 60 and 90 min. post-injection at capsaicin injection site and at 25 hr postinjection at NGF injection site. All measurements were recorded by the same assessor to reduce observer bias ( fig. 2 ).
Numeric rating scale. Ongoing pain was determined by modified numeric rating scale (NRS). The modified NRS is a scale of 0-10 with increments of 1, which allowed evaluation of both non-painful (from 0 to 5) and painful (from 5 to 10) sensations, where 0 = no sensation; 1 = vague perception of mild sensation; 2 = definite perception of mild sensation; 3 = vague perception of moderate sensation; and 4 = definite perception of moderate perception. For the painful sensations, the participants used the scale from 5 to 10 anchored at 5 = pain detection threshold (PDT); 6 = slight pain; 7 = moderate pain threshold (MPT); 8 = medium pain intensity; 9 = intense pain; and 10 = unbearable pain. Numbers and descriptions were visible for participants. The scale has been evaluated in several experimental and clinical studies and has proven reliable and robust [13] [14] [15] .
NGF injection. A single dose of 2.5 lg NGF (product number: 800479, human b-NGF, 25 lg/ml, Hospital Pharmacy, Skanderborg, Denmark) was injected intradermally in the thigh with a sterile insulin syringe.
Capsaicin injection. A single dose of capsaicin (Product no. 800644, capsaicin 1 mg/ml; Hospital Pharmacy Skanderborg, Denmark) was administered intradermally in the forearm (100 ll of 0.1% of capsaicin). Fig. 1 . Study flow chart. Each treatment period included two visits. Each treatment period was separated by a washout period of minimum 10 days between each period, and follow-up was carried out for safety evaluation.
Assessment of NGF and capsaicin effects. Allodynia, defined as a painful sensation elicited by gentle moving mechanical stimulation that is innocuous in normal skin area, was rated as absent or present. The area of allodynia was determined with a standardized soft brush (Somedic SenseLab AB, S€ osdala, Sweden). The brush was swept towards the injection site along eight vectors of the forearm/thigh intersecting at the injection site. The participants were asked to report when they experienced a painful sensation, and this site was marked. The areas of allodynia were transferred onto a transparency film without touching the subjects' skin, and the size of the affected areas was calculated in cm² (PDF Xchange Viewer, available online for free).
Punctuate hyperalgesia was determined by Pinprick (MRC Systems GmbH, Medizintechnische Systeme, Heidelberg, Germany). The mechanical pain detection threshold (MPT) was defined as the lowest force that elicited a sensation of pain. The area of punctate mechanical hyperalgesia was determined after capsaicin and NGF injection with pinprick. In normal skin, this stimulus is clearly suprathreshold for mechanical pain in all subjects. The filament was applied at right angles to each of a series of points 0.5 cm apart along each of eight radial paths converging at the injection site [16] . Stimulation started in normal skin proximal to the injection site. These starting points were well beyond the area where hyperalgesia is typically detected. This method was used to ensure that no single skin spot was stimulated twice, thus avoiding possible sensitization of cutaneous nociceptors by repeated stimulation of the skin. The points at which the participant reported abnormal tenderness (clearly enhanced pain compared with the immediately previous stimulation point) were marked on the skin with a soft pen. The areas of hyperalgesia were transferred onto a transparency film without touching the participants' skin, and the size of the affected areas is calculated (PDF Xchange Viewer).
Pressure pain detection thresholds were measured with an electronic pressure algometer (Somedic, H€ orby, Sweden) applied at the centre of the NGF injection site. The probe had a surface area of 1 cm². Pressure was increased at a rate of 30 kPa/s until the pain detection threshold was reached. Pressure pain detection threshold was defined as the point where pressure sensation turns to pain.
Thermal stimuli were applied to the skin at the centre of the NGF and capsaicin injection sites using a computerized contact heat-evoked potential stimulator with a stimulation surface area of 9 cm² (CHEPS; Medoc Ltd, Ramat Yishai, Israel). The temperature increased from a baseline 32°C to a maximum of 52°C with an increased rate of 1°C/ sec. The participants were instructed to stop the stimulation when the quality of the sensation changed from non-painful to painful. Three consecutive stimulations were performed, and between each stimulation, the temperature returned to baseline. The average temperature of the three consecutive stimulations was calculated and used as the contact heat pain detection threshold.
Safety assessment. Following side effects were recorded systematically at each visit including follow-up: pruritus; erythema; nausea; dizziness; and sedation. The intensity rating was defined as follows: (i) none, (ii) mild, (iii) moderate and (iv) severe. Side effects were classified into two groups: (i) central side effects (nausea, dizziness and sedation) and (ii) others (pruritus and erythema).
Statistics. The sample size was based on a power calculation which showed that 21 volunteers were required to achieve 80% power to detect a difference of 20% in the area of secondary hyperalgesia (p < 0.005) after capsaicin injection in treatment groups versus placebo.
Primary end-points: difference in capsaicin-induced allodynia and hyperalgesia between placebo and active treatments.
Secondary end-points: (i) difference in NGF-induced allodynia and hyperalgesia between placebo and active treatments; and (ii) side effects profile during treatment period.
Data were analysed using mixed models with drug (Diclometh 0.1%, Diclometh 0.2% or placebo) and time as factors for the primary end-point. For analyses of NGF effects, data were analysed with oneway ANOVA, as time-point was not a factor. Side effects were analysed using chi-square test. Stata 12.1 (StataCorp., Texas, TX, USA) was used in the statistical analysis. All statistical tests were two-sided, and p < 0.05 were considered significant.
Results
Twenty-one men were included, and all completed all three visits. They were all Caucasians with a mean age of 26.14 AE 5.3 years; weight 85.9 AE 14.7 kg and height 183.81 AE 6.10 cm. Date of first enrolment was 2 March 2016, and date of completion was 2 February 2017. Fig. 2 . Overview of one treatment period. Baseline (BL) tests (heat pain detection threshold, mechanical hyperalgesia and allodynia) were performed on the arm and thigh before gel application. Pressure pain detection threshold was only performed on the thigh. Gel was applied on the arm on visit 1 and on the thigh at visit 2 and removed after 45 min. Thereafter, capsaicin was injected in the arm and NGF was injected in the thigh on visit 1 and experimental pain tests were repeated three times on visit 1 on the arm and again once at visit 2 on the thigh.
Primary end-point: Effects on capsaicin-induced allodynia and hyperalgesia. Table 1 shows results for the primary end-points at time-point 30 min., and no effect on allodynia was seen at any other time-point (all p > 0.05). Diclometh 0.2% reduced the capsaicin-induced allodynia compared to placebo (p = 0.03, z = À2.18). No difference was seen between placebo and Diclometh at any time-point 0.1% (p = 0.99, z = À0.01; fig. 3 ). Neither Diclometh 0.1% nor Diclometh 0.2% affected the capsaicin-induced hyperalgesia to pinprick stimulation (p = 0.72, z = 0.35 and p = 0.56, z = À0.58) or contact heat stimulation at any time-point (p = 0.66, z = À0.43 and p = 0.11, z = À1.60; table 1).
Secondary end-point: Effects on NGF-induced allodynia and hyperalgesia. Table 2 shows results for the secondary end-points. Diclometh Secondary end-point: Safety. None of the participants reported any severe side effect. Table 3 summarizes central side effects. All central side effects were reported as mild, and no difference was found between treatments (p = 0.15; table 3). Regarding local side effects, no pruritus or erythema at the site of gel application was observed before capsaicin injection.
Discussion
A dose-dependent, antiallodynic effect of Diclometh was found. However, no effects on capsaicin-induced hyperalgesia were found and Diclometh did not affect NGF-induced hyperalgesia or allodynia. No serious local or central side effects were observed at any dosage of Diclometh.
One approach to reduce side effects related to oral NSAIDs has been to administer the drug to the skin overlying affected joints and muscles, relying on the premise that topical application will enhance local delivery at the expense of significant systemic levels. Topical NSAIDs have been widely used and studied. Penetration studies indicate that topically applied ibuprofen reaches therapeutic concentrations at the site of application. A previous study assessed the level of subcutaneous and muscle absorption of 800 mg of oral ibuprofen or 5% ibuprofen administered to the thigh. The ibuprofen concentrations in the dermis were 22.5-fold higher when delivered topically demonstrating effective tissue concentrations sufficient to provide any analgesic effect [17] . This was confirmed in the present study where an antiallodynic effect of Diclometh 0.2% was demonstrated in the absence of side effects. It could be speculated that analgesic effects from topically applied drugs are caused by effects in the central nervous system. Systemic absorption is needed for pronounced central effects and may lead to concentrations sufficient for central effects of diclofenac or methadone. One study found that serum concentrations of methadone associated with effective analgesia are not likely to be achieved by administration of methadone gel at doses below 45 mg/day (maximum concentration in the present study was 10 mg/day) [18] . Thus, any analgesic effect of topically applied methadone can be considered local. Additionally, systemic absorption would eventually lead to centrally induced side effects. Thus, the fact that no central side effects were reported in any of the applied dosages confirms that systemic drug concentrations were low and the reported effects can be considered local.
It cannot be excluded that the lack of effect in the present study might be due to low concentrations of Diclometh. The concentrations have been chosen based on pre-clinical animal studies where the authors found the synergistic combination of methadone and diclofenac (1:1) [10] . It was found that, in the capsaicin pain model, Diclometh antiallodynic effect was concentration-dependent; thus, it could be speculated that a higher concentration would demonstrate a more pronounced effect. Another factor that might affect the results is time of exposure. In the present study, the time of exposure was 45 min. However, shorter exposure time might be sufficient or longer exposure time might be necessary for a drug to penetrate through the skin and reach nerve terminals. In the present study, results were only significant at 30 min. after capsaicin injection and not over the full testing period. However, this may be explained by the fact that the allodynic/hyperalgesic effect of capsaicin is most pronounced at this time-point. Moreover, several end-points were evaluated, and only one primary end-point was significant. Thus, type II error cannot be excluded. However, human experimental studies should use several modalities and/or activation of several tissues for increased external validity [19] .
The present study was designed to investigate the efficacy and safety of different doses of Diclometh. For logistical reasons, it was not possible to include treatment arms with diclofenac and methadone as individual treatments, as this would have resulted in a five-arm study. Consequently, from the present study, it cannot be concluded if the observed effect results from methadone or diclofenac treatment or results from a synergistic effect. For topical NSAIDs in acute and chronic pain, the evidence quality has been assessed as moderate or high. This was based on large effect size (NNT below 2) [20] . For example, it has been demonstrated that topical NSAIDs were effective in reducing pain from acute musculoskeletal conditions [21] . Moreover, topical diclofenac was an effective treatment option for patients with neuropathic pain [22] . Topical methadone has been investigated to a lesser extent, and evidence for analgesic effect is not clear. Theoretically, the combination of drugs might be encouraging and an animal study demonstrated synergistic effect (increased potencies) of topical methadone and topical lidocaine [23] . In a post-operative pain study, it has been demonstrated that addition of an NMDA antagonist to opioid reduced pain in the early postoperative period [24] . An interesting aspect of such combinations targeting different peripheral mechanisms of the pain would be the ability of methadone and diclofenac to target the opioid, NMDA and COX systems located in dermal/epidermal junction. Our proposed gel formulation contains racemic methadone (D-and L-isoforms) and diclofenac. L-Methadone is a full mu-opioid agonist. D-Methadone also binds to the glutamatergic NMDA (N-methyl-D-aspartate) receptor and thus acts as a receptor antagonist against glutamate, while diclofenac is a non-selective COX-1 and COX-2 inhibitor. Molecular mechanisms of the synergy between topical methadone and diclofenac are still unclear, but this might be a reflection of their different sites of action. It is possible that enhanced analgesic effects between NSAIDs and opioids may occur as a combination of reduced neurotransmission and axonal conduction in dorsal root ganglion neurons. Alternatively, the potentiation of topical diclofenac analgesia by methadone may involve the intracellular signal transduction cascade. Recent results suggest that the L-arginine-nitric oxide-cGMP-potassium channel pathway is involved in the peripheral antinociceptive effect of diclofenac [25] . It is interesting to consider the possibility that the synergy between topical methadone and diclofenac is due to the conversion of independent pathways, which may be clinically beneficial. To our knowledge, the combination of methadone and diclofenac in gel, and in general, is used for the first time in human experimental pain models. Thus, results cannot be compared with others directly.
Methodological limitations.
The intradermal capsaicin model was chosen for various reasons. Capsaicin, when injected intradermally, produces an initial acute short-lasting neurogenic-like pain due to chemical inflammation in peripheral sensory fibres by acting on vanilloid receptors, which is followed by hyperalgesia and allodynia due to local and central sensitization of NMDA receptors [26] [27] [28] . Some experimental studies have indicated that there is an interaction between vanilloid and NMDA receptors in peripheral and central sites [29] [30] [31] [32] . In addition, TRPV1 immunoreactivity has shown to be present in cultured human keratinocytes, where its activation by capsaicin induces the production of pro-inflammatory mediators such as COX-2, IL-8 and PGE-2 [33] . In patients with traumatic or post-surgical neuropathic pain, abundance of TRPV1 fibres in painful, hypersensitive skin relative to normal skin, have been found. This correlates well with the TRPV1 involvement in mechanisms of pain and hyperalgesia in some types of post-traumatic chronic pain [6] . Thus, intradermal capsaicin activates a number of pro-nociceptive mechanisms that usually are expressed in the development of peripheral neuropathic pain syndromes. Therefore, in the present study, the capsaicin model was used, and as hypothesized, Diclometh reduced capsaicin-induced allodynia.
The NGF model has shown to induce long-term sensitization and hypersensitivity in human experimental pain models when injected intradermally and seems to mimic pain processes found in clinical situations [19] . Previous studies have shown high validity, and intradermal injections with NGF were capable of inducing reproducible hyperalgesia and allodynia [34] .
In the present study, the model seemed to work as there was a trend that heat pain threshold decreased from day one to two, but the lack of a clear reduction limits the interpretation of results.
No effects were demonstrated in the model of contact heat pain, although in an animal study, the same diclofenac/methadone combination (1:1) was effective in the thermal tail flick assay [10] . These discrepancies in drug effect emphasize the importance of translational human studies for evaluation of more accurate dosing and formulations for future clinical trials.
Healthy volunteers were included to avoid bias from the clinic, where confounding factors would affect the outcome [19] . A limitation in studying healthy volunteers is that results may not be translated directly into clinical situations where other factors could affect the outcome.
For example, as patients with pain will have all the 'bias' from the clinic and are of both gender, the external validity and translational impact of the present study may be limited. However, models inducing allodynia and/or hyperalgesia are relevant when investigating drug effects and mechanisms as they can act as proxies for clinical manifestations, as, for example, neuropathic pain [19, 35] . Thus, the results might give an indication of the analgesic effects of Diclometh in pain.
Conclusion
Indication of antiallodynic effect of Diclometh was found in the human experimental pain model of pain. Additionally, it was demonstrated that Diclometh was safe to use.
